Ken Griffin Compass Pathways PLC Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	N/A	-8,500 Reduced 29.72%	20,100 $171,000
Q2 2024 Aug 14, 2024	BUY	N/A	3,200 Added 12.6%	28,600 $244,000
Q1 2024 May 15, 2024	SELL	N/A	-40,100 Reduced 61.22%	25,400 $216,000
Q4 2023 Feb 14, 2024	SELL	N/A	-22,700 Reduced 25.74%	65,500 $559,000
Q3 2023 Nov 14, 2023	BUY	N/A	3,300 Added 3.89%	88,200 $753,000
Q2 2023 Aug 14, 2023	BUY	$7.79 - $10.69 $124,640 - $171,040	16,000 Added 23.22%	84,900 $725,000
Q1 2023 May 15, 2023	SELL	$7.32 - $10.85 $461,160 - $683,550	-63,000 Reduced 47.76%	68,900 $684,000
Q4 2022 Feb 14, 2023	SELL	$7.84 - $11.68 $291,648 - $434,496	-37,200 Reduced 22.0%	131,900 $1.06 Million
Q3 2022 Nov 14, 2022	BUY	$10.73 - $20.07 $314,389 - $588,051	29,300 Added 20.96%	169,100 $1.81 Million

151

33.6M

536K

582K

Ticker CMPS
Exchange NASDAQ
Sector Healthcare
Industry Medical Care Facilities
Shares Outstandng 42,522,400
Market Cap $363M
Description
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. Th...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.